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Sir Thomas More, the sixteenth century philosopher and author who was 
beheaded (and later canonised) for his opposition to Henry VIII’s reformation, 
first wrote that: “to seek out one line in his books would be to go look (for) a 
needle in a meadow.” Almost 500 years later, attempts to identify a single 
pathogenic variant in more than 20,000 genes that make up the human genome 
may be considered a similarly thankless task. In usual practice, a well-
established clinical phenotype will dramatically reduce the size of the ‘meadow’ 
or ‘haystack’ and improve the chances of identifying the ‘needle’. However, 
idiopathic ventricular fibrillation (IVF) presents a unique challenge: a life-
threatening condition without clinical signs other than the sudden and 
unpredictable onset of ventricular fibrillation. 
IVF is diagnosed: “in a resuscitated cardiac arrest victim[…]in whom known 
cardiac respiratory, metabolic and toxicological etiologies have been excluded 
through clinical evaluation”1. Advances in the diagnosis of inherited arrhythmia 
syndromes have demonstrated that phenotypes may be subtle and highly 
variable. Detailed clinical evaluation in patients previously labeled as IVF may 
reveal diagnoses including the long QT  and Brugada syndromes, 
arrhythmogenic right ventricular cardiomyopathy and catecholaminergic 
polymorphic ventricular tachycardia. Furthermore, survivors of an initially 
unexplained cardiac arrest may develop a detectable phenotype years after the 
index event2 and some victims of sudden unexpected death with a normal post-
mortem examination (i.e. Sudden Arrhythmic Death Syndrome, SADS), which 
may be considered analogous to IVF, may have pathogenic variants in 
cardiomyopathy-associated genes identified by molecular autopsy3. Therefore 
electrical instability and the risk of life-threatening arrhythmias may precede 
clinically or pathologically identifiable phenotypes and a proportion of IVF is 
attributable to primary arrhythmia syndromes or cardiomyopathies without an 
expressed phenotype. In other IVF cases, monogenic causes have been identified.  
These include: the well established Dutch founder haplotype in the arrhythmia 
gene DPP64; pathogenic variants in calmodulin5 and the transcription factor 
IRX36; and a loss of function variant in RYR27. 
Genetic testing may therefore diagnose a concealed arrhythmia syndrome or the 
genetic etiology of IVF. However, genetic testing in such cases is not currently 
recommended with high costs and frequent identification of variants of 
uncertain significance (VUS) cited as reasons in the 2011 HRS/EHRA expert 
consensus document8. As sequencing technology becomes increasingly rapid, 
affordable and widely available, reappraisal of this recommendation may be 
required. 
In this issue of Heart Rhythm, Visser et. al.9 describe the findings of an extended 
next generation sequencing panel of 179 genes in 33 IVF survivors and report a 
yield of only one pathogenic or likely pathogenic variant - a truncating variant in 
the titin (TTN) gene seen in a single patient.  
The authors are to be congratulated on their efforts to thoroughly evaluate their 
cohort.  They completed and supplemented the original historical assessments in 
order to exclude alternative causes of VF.   However, despite their attempts, 
clinical evaluation was not exhaustive. Although all patients had a 12-lead ECG, 
coronary imaging, echocardiography, exercise and ambulatory ECG, cardiac MRI 
was only performed in 45% and sodium channel blocker provocation in 58%. No 
comment was made of the use of high right ventricular lead ECGs either at rest or 
during provocation testing. 
Whilst at first glance their findings portray a negative message regarding the 
utility of genetic testing in IVF, it must be noted that these 33 patients were a 
sub-selection of a larger cohort of apparent IVF survivors in whom previous 
genetic testing had already proven negative. This had consisted of either 
phenotype targeted testing or a 33-gene panel of predominantly arrhythmia 
syndrome associated genes10. The yield of the first stage of genetic testing is 
reported as 15%10, with the 33-gene panel in particular identifying pathogenic 
or likely pathogenic variants in: KCNQ1 (associated with LQTS type 1); MYL2 
(associated with hypertrophic cardiomyopathy (HCM)); and DPP6 in 3 
individuals.  
Of the 179 genes included in second-line testing only a small number have been 
reliably associated with either IVF or with established phenotypes that carry a 
risk of ventricular fibrillation; variants in sarcomeric genes MYBPC3, MYH7, 
TNNI3 and TNNT2 are recognized causes of HCM, while truncating variants in 
TTN are seen in cases of dilated cardiomyopathy and peri-partum 
cardiomyopathy. For the remaining genes, evidence that variants are associated 
with ‘sudden death’ phenotypes is limited. It is therefore unsurprising that 
inclusion of these genes in large panels such as this offers little added yield. 
Furthermore, as the authors state, the ‘genetic noise’ inevitably increases as 
more genes are tested. One or more VUS was identified in 24% of patients with 
the initial 33-gene panel, which increased to 34% overall with the extended 
panel. 
Genetic testing in IVF therefore offers a modest but potentially significant 
diagnostic yield, identifying either rare monogenic causes of IVF or concealed 
arrhythmia syndromes where clinical evaluation has failed. It should therefore 
be considered in conjunction with thorough and systematic clinical evaluation of 
probands, where it may guide treatment, and relatives, where it may aid the 
identification of other at-risk individuals. While testing should be comprehensive, 
in that genes associated with both arrhythmia syndromes and cardiomyopathies 
may be included, the temptation to increase yield through ever expanding panels 
should be avoided and only those genes with robust association with disease 
should be included. Due to the relatively high rate of VUSs, testing should be 
limited to experienced centres with the ability and infrastructure to assess 
variants and robustly follow-up those individuals until the significance of a 
variant can be determined.  
Future research should also be focused upon identifying potential polygenic and 
non-genetic causes that likely underpin much of IVF. These may have wider 
implications for the understanding of the mechanisms of ventricular fibrillation 
in other more common scenarios such as ischaemic heart disease. Rather than 
finding the one needle, we need to understand the interaction between the 
blades of grass in the stack. 
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